Arvinas Inc (OQ:ARVN)

Apr 11, 2024 07:00 am ET
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treat
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it has entered into an exclusive strategic license agreement with Novartis (NYSE: NVS) for the...
Mar 18, 2024 04:40 pm ET
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Noah Berkowitz, M.D., Ph.D., to the role of Chief Medical Officer and a...
Mar 04, 2024 07:00 am ET
Arvinas to Participate in Upcoming Investor Conferences
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor conferences: Leerink Partners...
Feb 27, 2024 07:00 am ET
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a...
Feb 20, 2024 04:05 pm ET
Arvinas Announces Chief Financial Officer Transition
Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that after more than a decade with the company, Sean Cassidy, C.P.A, Chief Financial Officer...
Feb 20, 2024 07:00 am ET
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the first subject was dosed in its Phase 1 clinical trial of ARV-102, the Company’s first...
Feb 14, 2024 08:00 am ET
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced that the first patient has been dosed in its Phase 1b/2 clinical trial evaluating the combination of...
Feb 06, 2024 06:45 am ET
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of vepdegestrant (ARV-471) for monotherapy in the treatment of adults...
Feb 01, 2024 04:30 pm ET
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ron Peck, M.D., Chief Medical Officer, and Randy Teel, Ph.D., Senior Vice President,...
Jan 16, 2024 05:01 pm ET
Arvinas Appoints Jared Freedberg as General Counsel
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Jared Freedberg, J.D., has joined the company as General Counsel. “We are thrilled to...
Dec 05, 2023 10:52 pm ET
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that a conference call and webcast will be held with executives from Arvinas and Pfizer Inc....
Dec 05, 2023 01:33 pm ET
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced clinical data for vepdegestrant (ARV-471), a novel oral PROteolysis TArgeting Chimera (PROTAC®) estrogen receptor (ER) degrader, in combination with palbociclib (IBRANCE®)....
Nov 28, 2023 05:05 pm ET
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
NEW HAVEN, Conn. and NEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced that updated clinical trial data for vepdegestrant (ARV-471) will be presented at the 2023 San...
Nov 27, 2023 07:00 am ET
Arvinas Announces Oversubscribed $350 Million Private Placement
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it has entered into a securities purchase agreement with a select group of institutional...
Nov 07, 2023 07:00 am ET
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate...
Nov 02, 2023 07:00 am ET
Arvinas to Participate in Upcoming Investor Conferences
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in five upcoming investor conferences: Truist Securities...
Oct 22, 2023 07:00 am ET
Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the presentation of interim data from the Company’s Phase 1/2 clinical trial for...
Oct 18, 2023 07:00 am ET
Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that nearly 200 employees participated in the Company’s second annual “Arvinas Impact Day,” a...
Oct 15, 2023 06:07 pm ET
Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it will present updated Phase 1/2 trial data for bavdegalutamide (ARV-110) at the 2023...
Oct 15, 2023 06:05 pm ET
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023
Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated Phase 1/2 data for vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Annual Congress. Vepdegestrant is a novel oral...
Sep 01, 2023 07:00 am ET
Arvinas to Participate in Upcoming Investor Conferences
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor conferences: Wells Fargo 2023...
Aug 08, 2023 07:00 am ET
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update....
Jul 31, 2023 04:30 pm ET
Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed
Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced that the U.K. Innovative Licensing and Access Pathway Steering Group, which consists of The All Wales Therapeutics and Toxicology Centre (AWTTC), The Medicines and Healthcare...
Jul 06, 2023 09:00 am ET
Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination
Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced a clinical trial collaboration and supply agreement with Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc....
Jun 15, 2023 04:30 pm ET
Arvinas Announces Changes to its Board of Directors
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Timothy Shannon, M.D., current Chairperson and a member of the company’s Board of...
Jun 08, 2023 07:00 am ET
Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced promising interim data from the Company’s Phase 1/2 dose escalation and expansion trial of...
Jun 05, 2023 07:00 am ET
Arvinas to Participate in Upcoming Investor Conferences
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences: Jefferies Healthcare...
May 08, 2023 07:00 am ET
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated data related to vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress. Vepdegestrant is a...
May 05, 2023 07:00 am ET
Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update....
May 03, 2023 07:00 am ET
Arvinas to Present at the Bank of America Securities 2023 Healthcare Conference
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Sean Cassidy, Chief Financial Officer, and Randy Teel, Ph.D., Senior Vice President,...
May 02, 2023 01:00 pm ET
Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical Trial
NEW HAVEN, Conn. and SAN FRANCISCO, May 2, 2023 /PRNewswire/ -- Arvinas, Inc. (Nasdaq: ARVN) and Quantum Leap Healthcare Collaborative™ today announced that Arvinas' vepdegestrant (ARV-471), a novel PROTAC® estrogen receptor (ER) protein degrader being co-developed with Pfizer Inc. will be evaluated in the ongoing I-SPY TRIAL endocrine program sponsored by Quantum Leap. This study targets patients with newly diagnosed ER positive invasive cancer. Vepdegestrant is in Phase 3 clinical development for the treatment of patients with locally advanced or metastatic ER positive/human epidermal grow
Apr 21, 2023 04:00 pm ET
Arvinas to Present at Stifel Targeted Oncology Day
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, and Sean Cassidy, Chief Financial Officer,...
Apr 03, 2023 07:00 am ET
Arvinas Appoints Kelly Page as Senior Vice President, Global Head of Oncology Strategy and Program Leadership
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Kelly Page has joined the company as Senior Vice President, Global Head of Oncology...
Feb 27, 2023 04:00 pm ET
Arvinas to Participate in Upcoming Investor Conferences
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences: Cowen 43rd Annual...
Feb 23, 2023 07:00 am ET
Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a...
Feb 06, 2023 04:30 pm ET
Arvinas to Participate in Upcoming Investor Conferences
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor conferences: Guggenheim Oncology...
Jan 04, 2023 07:00 am ET
Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer of Arvinas, will present a...
Dec 16, 2022 09:00 am ET
Arvinas Announces Changes to its Board of Directors
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Brad Margus, M.B.A., has stepped down from the company’s Board and Everett Cunningham has...
Nov 22, 2022 07:12 am ET
Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)
Arvinas, Inc. (Nasdaq: ARVN) today announced initial results from the Phase 2 cohort expansion portion (VERITAC) of a phase 1/2 study with ARV-471, a novel PROTAC® estrogen receptor (ER) protein degrader. ARV-471 is being co-developed with Pfizer...
Nov 08, 2022 07:00 am ET
Arvinas Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate...
Nov 01, 2022 04:00 pm ET
Arvinas to Present at Upcoming Conferences
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in two upcoming conferences: Society for Neuroscience (SFN) Annual...
Oct 27, 2022 07:00 am ET
Arvinas Announces Winner of the 2022 Arvinas Early Career Researcher Award
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation (TPD), announced Katherine Donovan, Ph.D. of the Dana-Farber Cancer Institute/Harvard Medical School as the...
Oct 03, 2022 07:00 am ET
Arvinas Appoints Paul McInulty as Senior Vice President, Regulatory Affairs
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Paul McInulty has joined the company as Senior Vice President, Regulatory Affairs. “We...
Sep 30, 2022 09:00 am ET
Arvinas Gives Back to Local Greater New Haven Community
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that nearly 200 employees participated in the Company’s inaugural “Arvinas Impact Day,” a...
Sep 26, 2022 07:00 am ET
Arvinas to Present at Bank of America Securities Precision Oncology Conference
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Bank of America Securities...
Sep 13, 2022 10:17 am ET
hC Bioscience Appoints Brad Margus to its Board of Directors
hC Bioscience, Inc., a company developing first-in-class tRNA-based therapeutics targeting protein dysfunction in genetically defined diseases, today announced the appointment of industry veteran Brad Margus to its board of directors. “We are...
Aug 31, 2022 07:00 am ET
Arvinas to Present at Upcoming Investor Conferences
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in three upcoming investor conferences: Citi 17th Annual BioPharma...
Aug 18, 2022 04:01 pm ET
Arvinas Announces Changes to its Board of Directors
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Liam Ratcliffe, M.D., Ph.D. has stepped down from the company’s Board and John Young has...
Aug 15, 2022 07:00 am ET
Arvinas Appoints Lisa Sinclair as Senior Vice President, Corporate Operations
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Lisa Sinclair has joined the company as Senior Vice President, Corporate Operations....
Aug 04, 2022 07:00 am ET
Arvinas Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update....
Aug 01, 2022 07:00 am ET
Arvinas Appoints John Northcott as Chief Commercial Officer
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Northcott has joined the company in a newly created position of Chief Commercial...
Jun 02, 2022 04:00 pm ET
Arvinas to Present at Goldman Sachs 43rd Annual Global Healthcare Conference
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global...
Jun 01, 2022 08:00 am ET
Arvinas Launches Global Early Career Researcher Award and Announces Call for Nominations
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced a global call for entries for their inaugural Early Career Research Award. This award will...
May 09, 2022 10:00 am ET
GNS Healthcare and Arvinas Enter into Neuroscience Drug Discovery Collaboration
SOMERVILLE, Mass., May 9, 2022 /PRNewswire/ -- GNS Healthcare, the leader in the use of "Virtual Patients", Causal AI and simulation technology for biopharmaceutical companies, today announced a collaboration with Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, to generate insights to help accelerate drug development for neurodegenerative diseases. 
May 05, 2022 07:00 am ET
Arvinas Reports First Quarter 2022 Financial Results and Provides Corporate Update
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update....
May 03, 2022 07:00 am ET
Arvinas to Present at Bank of America Securities 2022 Healthcare Conference
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Bank of America Securities 2022...
Mar 04, 2022 07:00 am ET
Arvinas to Present at Upcoming Investor Conferences
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in two upcoming virtual investor conferences: Cowen & Co. 42nd...
Feb 28, 2022 07:00 am ET
Arvinas Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a...
Feb 17, 2022 08:00 am ET
Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced completed Phase 1 and interim Phase 2 ARDENT data for bavdegalutamide (ARV-110), a novel...
Feb 14, 2022 06:04 pm ET
Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to be Presented at 2022 ASCO GU Meet
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the presentation of new data showing that bavdegalutamide (also known as ARV-110), a novel...
Feb 03, 2022 04:30 pm ET
Arvinas to Present at Upcoming Investor Conferences
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in two upcoming virtual investor conferences: Guggenheim Oncology...
Dec 10, 2021 08:10 am ET
Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced an update on Phase 1 dose escalation data of ARV-471, a novel PROTAC® estrogen receptor (ER) degrader, which is being co-developed for the treatment of patients with locally...
Nov 19, 2021 09:55 am ET
Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium
Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced today that updated safety and efficacy data from the Phase 1 dose escalation trial of ARV-471, a novel oral estrogen receptor (ER)-targeting PROteolysis TArgeting Chimera (PROTAC®)...
Nov 10, 2021 07:00 am ET
Arvinas to Present at Stifel 2021 Virtual Healthcare Conference
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Sean Cassidy, Chief Financial Officer, and Ian Taylor, Ph.D., Chief Scientific Officer,...
Nov 03, 2021 07:00 am ET
Arvinas Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate...
Oct 20, 2021 04:02 pm ET
Neurona Therapeutics Appoints Brad Margus to its Board of Directors
Neurona Therapeutics, a biotherapeutics company advancing restorative neural cell therapies for the treatment of chronic neurological disorders, today announced that it has appointed Brad Margus to its board of directors. Mr. Margus brings over 30...
Sep 01, 2021 07:00 am ET
Arvinas to Participate in Upcoming Virtual Investor Conferences
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in two upcoming virtual investor conferences: Citi 16th Annual...
Aug 09, 2021 09:16 am ET
Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas
HONG KONG, Aug. 9, 2021 /CNW/ -- Insilico Medicine is proud to announce an R&D collaboration with Arvinas (NASDAQ: ARVN). This strategic partnership will involve Insilico Medicine's AI-augmented platforms and close cooperation between Arvinas' and Insilico Medicine's scientists on novel PROTACs. The collaboration will include the design of transformative treatment modalities for existing and next-generation targets; and demonstrate the impact of combining AI with one of the most significant breakthrough technologies in drug discovery - PROTACs.
Aug 09, 2021 09:16 am ET
Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas
HONG KONG, Aug. 9, 2021 /PRNewswire/ -- Insilico Medicine is proud to announce an R&D collaboration with Arvinas (NASDAQ: ARVN). This strategic partnership will involve Insilico Medicine's AI-augmented platforms and close cooperation between Arvinas' and Insilico Medicine's scientists on novel PROTACs. The collaboration will include the design of transformative treatment modalities for existing and next-generation targets; and demonstrate the impact of combining AI with one of the most significant breakthrough technologies in drug discovery - PROTACs.
Aug 05, 2021 07:00 am ET
Arvinas Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update....
Jul 23, 2021 09:31 am ET
Thinking about trading options or stock in Snap, Twitter, Trade Desk, Arvinas, or Intel Corp?
NEW YORK, July 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNAP, TWTR, TTD, ARVN, and INTC.
Jul 22, 2021 07:00 am ET
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471
Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen...
Jun 07, 2021 05:19 pm ET
Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today joined state and local officials, fellow tenants, and community partners, in a groundbreaking ceremony...
Jun 03, 2021 07:00 am ET
Arvinas to Present at the 42nd Annual Goldman Sachs Global Healthcare Conference
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ron Peck, M.D., Chief Medical Officer, and Sean Cassidy, Chief Financial Officer, will...
May 20, 2021 04:30 pm ET
Arvinas to Present at the UBS Global Healthcare Virtual Conference
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer and Ian Taylor, Ph.D., Chief...
May 04, 2021 02:52 pm ET
Arvinas Signs Lease for New Space Within Downtown Crossing Development in New Haven
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will be leasing three of the 10 floors at 101 College Street in New Haven, Conn....
May 04, 2021 07:00 am ET
Arvinas Reports First Quarter 2021 Financial Results and Provides Corporate Update
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate...
Apr 05, 2021 04:30 pm ET
Arvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual...
Mar 10, 2021 04:30 pm ET
Arvinas to Participate in Upcoming Virtual Investor Conferences
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in two upcoming virtual investor conferences. John Houston, Ph.D.,...
Mar 01, 2021 07:00 am ET
Arvinas Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided...
Feb 08, 2021 04:30 pm ET
Arvinas to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer and Ian Taylor, Ph.D., Chief...
Dec 28, 2020 04:30 pm ET
Arvinas, Inc. Announces Exercise of Underwriters’ Option to Purchase Additional Shares
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC® Discovery Engine, today announced that the underwriters of its previously announced...
Dec 15, 2020 08:34 pm ET
Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC® Discovery Engine, today announced the pricing of an underwritten public offering of 5,714,286...
Dec 14, 2020 04:06 pm ET
Arvinas, Inc. Announces Proposed Offering of Common Stock
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC® Discovery Engine, today announced that it is commencing an underwritten public offering of...
Dec 14, 2020 07:30 am ET
Thinking about buying stock in Pfizer, Moderna, Arvinas, Veru, or Alexion Pharmaceuticals?
NEW YORK, Dec. 14, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PFE, MRNA, ARVN, VERU, and ALXN.
Dec 14, 2020 07:00 am ET
Arvinas Releases Interim Clinical Data Further Demonstrating the Powerful Potential of PROTAC® Protein Degraders ARV-471 and ARV-110
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation using its PROTAC® Discovery Engine, today announced clinical program updates for its PROTAC® protein...
Dec 11, 2020 04:15 pm ET
Arvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC® Protein Degrader Development Programs
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will host a live webcast presentation on Monday, December 14, 2020 at 8:00 a.m. ET to...
Nov 25, 2020 07:00 am ET
Arvinas to Participate in Upcoming Virtual Investor Conferences
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming virtual investor conferences: Piper...
Nov 05, 2020 07:00 am ET
Arvinas Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today reported financial results for the third quarter ended September 30, 2020 and provided a corporate...
Oct 14, 2020 07:00 am ET
Arvinas Announces Pipeline Programs Targeting Validated and Classically “Undruggable” Disease-Causing Proteins
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced platform updates and disclosed five additional programs from its preclinical pipeline....
Oct 06, 2020 05:17 pm ET
Arvinas to Present at the 3rd Annual Targeted Protein Degradation Summit
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer, will present a keynote...
Sep 04, 2020 07:00 am ET
Arvinas to Present at the Citi 15th Annual BioPharma Virtual Conference
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the...
Aug 07, 2020 07:00 am ET
Arvinas to Present at the 2020 Wedbush PacGrow Virtual Healthcare Conference
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ron Peck, M.D., Chief Medical Officer, will participate in a fireside chat at the 2020...
Aug 04, 2020 07:00 am ET
Arvinas Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter ended June 30, 2020 and provided a corporate...
Jun 29, 2020 04:30 pm ET
Arvinas Appoints Wendy Dixon, Ph.D., to its Board of Directors
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Wendy Dixon, Ph.D., has joined its Board of Directors. Dr. Dixon is a well-respected...
Jun 17, 2020 07:00 am ET
Arvinas to Present Virtually at the BMO 2020 Prescriptions for Success Healthcare Conference
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the...
Jun 11, 2020 07:00 am ET
Arvinas Appoints Linda Bain to its Board of Directors
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Linda Bain has joined its Board of Directors. Ms. Bain, who is currently the Chief...
Jun 05, 2020 07:00 am ET
Arvinas to Present Virtually at the Goldman Sachs 41st Annual Global Healthcare Conference
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ron Peck, M.D., Chief Medical Officer, will participate in a fireside chat at the Goldman...
May 29, 2020 07:00 am ET
Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTAC® Protein Degrader ARV-110 in Patients with Metastatic Castration-Resistant Prostate Cancer
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced updated data from the dose escalation portion of the company’s Phase 1/2 clinical trial of...
May 20, 2020 04:30 pm ET
Arvinas to Hold Virtual 2020 Annual Meeting of Stockholders
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that its 2020 Annual Meeting of Stockholders, to be held on Wednesday, June 3, 2020 at 8:30...
May 13, 2020 05:49 pm ET
Arvinas Announces Updated Phase 1 Data Demonstrating Clinical Activity of PROTAC® Protein Degrader ARV-110 in Patients with Refractory Prostate Cancer
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced updated safety and initial efficacy data contained in an abstract scheduled as an oral...
Apr 28, 2020 07:00 am ET
Arvinas Reports First Quarter 2020 Financial Results and Provides a Corporate Update
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the first quarter ended March 31, 2020 and provided a corporate update....
Apr 13, 2020 04:54 pm ET
Arvinas Provides Update on Business Continuity Related to the Impact of the COVID-19 Pandemic
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today provided an update regarding the impact of the COVID-19 pandemic on its overall business continuity,...
Mar 31, 2020 07:00 am ET
Arvinas to Present at the American Society of Clinical Oncology Annual Meeting
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the acceptance of an abstract for presentation at the American Society of Clinical Oncology...
Mar 16, 2020 07:00 am ET
Arvinas Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided a...
Nov 27, 2019 07:30 am ET
Arvinas to Present at the 31st Annual Piper Jaffray Healthcare Conference
Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the 31st Annual Piper...
Nov 21, 2019 07:30 am ET
Arvinas Appoints Laurie Smaldone Alsup, M.D., to Board of Directors
Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced today that Laurie Smaldone Alsup, M.D., has joined its board of directors. Dr. Smaldone Alsup, who is currently the...
Nov 06, 2019 09:40 pm ET
Arvinas, Inc. Announces Pricing of Public Offering of Common Stock
Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the pricing of an underwritten public offering of 4,545,455 shares of its common stock at a price of $22.00...
Nov 06, 2019 04:01 pm ET
Arvinas, Inc. Announces Proposed Offering of Common Stock
Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it is commencing an underwritten public offering of $90.0 million of shares of its common stock.  In...
Nov 04, 2019 05:00 pm ET
Arvinas Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today reported financial results for the third quarter of 2019 and provided a corporate update. “We...
Oct 23, 2019 06:30 am ET
Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders
Arvinas, Inc., (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced a platform data update that includes initial safety, tolerability, and pharmacokinetic data from the...
Oct 17, 2019 07:00 am ET
Arvinas to Present Initial Data from Ongoing Clinical Trials and a Pipeline Update at the 2nd Targeted Protein Degradation Summit
Arvinas Inc., (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it will be participating in multiple sessions of the 2nd Targeted Protein Degradation Summit.  In one of...
Oct 02, 2019 07:00 am ET
Arvinas Strengthens Scientific Advisory Board with Leaders in Oncology and Neurological Disorders
Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced that six new thought leaders will join the company’s scientific advisory board (SAB). The new members are Tomasz M....
Oct 01, 2019 04:00 am ET
Bayer and Arvinas Unveil Targeted Protein Degradation Joint Venture, Oerth Bio
Bayer and Arvinas, Inc., a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced they have finalized the terms of their agreement to jointly launch a new company, Oerth Bio (pronounced “Earth”),...
Aug 27, 2019 07:00 am ET
Arvinas Announces the Initiation of Patient Dosing in a First-in-Human Phase 1 Study of ARV-471, an Estrogen Receptor-Targeting PROTAC® Protein Degrader
Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the initiation of patient dosing in its second clinical program. The Phase 1 clinical trial of ARV-471, an...
Aug 07, 2019 07:00 am ET
Arvinas To Present at the Wedbush PacGrow Healthcare Conference
Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the company is scheduled to present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday,...
Aug 05, 2019 07:00 am ET
Arvinas Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter of 2019 and provided a corporate update. “We made significant...
Jul 29, 2019 07:00 am ET
Arvinas Appoints Ronald Peck, M.D. as Chief Medical Officer
Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced today the appointment of Ronald Peck, M.D. to the newly created position of Chief Medical Officer (CMO). Dr. Peck...
Jul 25, 2019 07:00 am ET
Arvinas Strengthens Board of Directors with Addition of Leslie Norwalk
Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced today that Leslie Norwalk, Esq., will join its Board of Directors. Ms. Norwalk provides strategic counsel to a...
Jul 18, 2019 07:00 am ET
Arvinas to Present Preclinical Tau-Directed PROTAC® Protein Degrader Data at Alzheimer's Association International Conference
Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced it will present preclinical data from its tau-targeted PROTAC® protein degrader program at the Alzheimer's...
Jun 25, 2019 07:00 am ET
Arvinas Receives Authorization to Proceed for ARV-471, a PROTAC® Protein Degrader to Treat Patients with Locally Advanced or Metastatic ER+ / HER2- Breast Cancer
Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug...
Jun 20, 2019 08:30 am ET
Arvinas to Present at the BMO Prescriptions for Success Healthcare Conference
Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the BMO Prescriptions for...
Jun 06, 2019 07:00 am ET
Arvinas to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Goldman Sachs 40th Annual...
Jun 04, 2019 07:00 am ET
Bayer and Arvinas to Collaborate on Human PROTAC® Therapies and Launch a Separate Joint Venture to Develop Agricultural PROTAC® Applications
Bayer and Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies to degrade disease-causing proteins, today announced an agreement to leverage Arvinas’ novel PROTAC® protein degrader technology to develop new...
May 29, 2019 07:00 am ET
Arvinas Receives Fast Track Designation for its Targeted Protein Degrader ARV-110 as a Treatment for Men with Metastatic Castration-Resistant Prostate Cancer
Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies that degrades disease-causing proteins, today announced that its lead PROTAC® protein degrader, ARV-110, has been granted Fast Track designation by the U.S....
May 08, 2019 07:00 am ET
Arvinas Reports First Quarter Financial Results and Provides Corporate Update
Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies that degrades disease-causing proteins, today reported financial results for the first quarter of 2019 and provided a corporate update. “The first...
Apr 02, 2019 07:00 am ET
Arvinas Strengthens Management Team with Internal Appointments of Andy Crew, Ph.D. as Chief Technology Officer and Ian Taylor, Ph.D. as Chief Scientific Officer
Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies that degrades disease-causing proteins, announced that two members of the senior leadership team were appointed to expanded roles at the company.  Andy...
Mar 26, 2019 07:00 am ET
Arvinas Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies that degrade disease-causing proteins, today reported financial results for the fourth quarter and full year ended December 31, 2018 and provided a...
Mar 25, 2019 07:00 am ET
Arvinas Announces Initiation of Patient Dosing in the First Phase 1 Clinical Trial of PROTAC™ Protein Degrader, ARV-110
Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies that degrade disease-causing proteins, today announced the initiation of patient dosing in its Phase 1 clinical trial of ARV-110, the company’s oral...
Feb 07, 2019 04:30 pm ET
Arvinas Announces Poster Presentation at ASCO 2019 Genitourinary Cancers Symposium
Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced that it will present a poster at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO...
Jan 04, 2019 05:00 pm ET
Arvinas Receives Authorization to Proceed for its IND Application for PROTAC™ Therapy to Treat Patients with Metastatic Castration-Resistant Prostate Cancer
Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug...
Dec 07, 2018 07:00 pm ET
Arvinas Presents Preclinical Data on Protein Degrader, ARV-471, at the 2018 San Antonio Breast Cancer Symposium (SABCS)
Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today presented positive preclinical data on the company's lead clinical candidate, ARV-471, for advanced or metastatic...
Nov 20, 2018 06:00 am ET
Arvinas To Present at the 30th Annual Piper Jaffray Healthcare Conference
Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced that John G. Houston, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 30th...
Oct 23, 2018 07:30 am ET
Arvinas to Present at Two Protein Degradation Conferences
Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced it will be presenting at two upcoming conferences focused on protein degradation. The first is the Targeted Protein...
Sep 26, 2018 08:06 pm ET
Arvinas Announces Pricing of Initial Public Offering
Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies to degrade...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.